Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Hot Drugs 2004
  • Published:

Infectious diseases

Nature Reviews Drug Discovery volume 3, pages S26–S32 (2004)Cite this article

Brand name: Fuzeon Companies: Trimeris/Roche Approved: 13 March 2003 Condition treated: HIV-1 infection Action: inhibits viral entry into host cells CAS number: 159519-65-0

Basis of discovery

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mode of action of enfuvirtide.
Figure 2: Atazanavir sulphate.
Figure 3: Market for anti-HIV drugs.
Figure 4: Daptomycin.
Figure 5: United States antibacterial market in US $ million in 2003.

References

  1. Pomerantz, R. J. & Horn, D. L. Twenty years of therapy for HIV-1 infection. Nature Med. 9, 867–873 (2003).

    Article  CAS  Google Scholar 

  2. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Disc. 1, 13–25 (2002).

    Article  CAS  Google Scholar 

  3. Wild, C. T. et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770–9774 (1994).

    Article  CAS  Google Scholar 

  4. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302–1307 (1998).

    Article  CAS  Google Scholar 

  5. FDA Drug Approvals List [online] (cited 14 April 2004) <http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf> (2003).

  6. Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175–2185 (2003).

    Article  CAS  Google Scholar 

  7. Lazzarin, A. et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186–2195 (2003).

    Article  CAS  Google Scholar 

  8. Carr, A. Toxicity of antiretroviral therapy and implications for drug development. Nature Rev. Drug Disc. 2, 624–634 (2003).

    Article  CAS  Google Scholar 

  9. Fässler, A. et al. Aza-peptide analogues as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. J. Med. Chem. 39, 3203–3216 (1996).

    Article  Google Scholar 

  10. Priestle, J. P. et al. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3, 381–389 (1995).

    Article  CAS  Google Scholar 

  11. Bold, G. et al. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 41, 3387–3401 (1998).

    Article  CAS  Google Scholar 

  12. Robinson, B. S. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44, 2093–2099 (2000).

    Article  CAS  Google Scholar 

  13. FDA Drug Approvals List [online] (cited 14 April 2004). <http://www.fda.gov/cder/foi/label/2003/21567_reyataz_lbl.pdf> (2003).

  14. Coates, A. et al. The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug Disc. 1, 895–910 (2002).

    Article  CAS  Google Scholar 

  15. Walsh, C. Where will new antibiotics come from? Nature Rev. Microbiol. 1, 65–69 (2003).

    Article  CAS  Google Scholar 

  16. Lowy, F. D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265–1273 (2003).

    Article  CAS  Google Scholar 

  17. Tally, F. P. & DeBruin, M. F. Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46, 523–526 (2000).

    Article  CAS  Google Scholar 

  18. FDA Drug Approvals List [online] (cited 14 April 2004). <http://www.fda.gov/cder/foi/label/2003/21572_cubicin_lbl.pdf> (2003).

  19. Debono, M. et al. Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032). J. Antibiot. (Tokyo) 41, 1093–1105 (1988).

    Article  CAS  Google Scholar 

  20. Fuchs, P. C. et al. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49, 467–470 (2002).

    Article  CAS  Google Scholar 

  21. Appelbaum, P. C. & Hunter, P. A. The fluoroquinolone antibacterials: past, present and future perspectives. Intl J. Antimicrob. Agents 16, 5–15 (2000).

    Article  CAS  Google Scholar 

  22. Hong, C. Y. Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation. II Farmaco 56, 41–44 (2001).

    Article  CAS  Google Scholar 

  23. FDA Drug Approvals List [online] (cited 14 April 2004). <http://www.fda.gov/cder/foi/label/2003/21158_factive_lbl.pdf> (2003).

  24. Schinazi, R. F. et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36, 2423–2431 (1992).

    Article  CAS  Google Scholar 

  25. Richman, D. D. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Ther. 6, 83–88 (2001).

    CAS  Google Scholar 

  26. FDA Drug Approvals List [online] (cited 14 April 2004). <http://www.fda.gov/cder/foi/label/2003/21500_Emtriva_lbl.pdf> (2003).

  27. Hainer, B. L. Dermatophyte infections. Am. Fam. Physician 67, 101–108 (2003).

    PubMed  Google Scholar 

  28. Odds, F. C. et al. Antifungal agents: mechanisms of action. Trends Microbiol. 11, 272–279 (2003).

    Article  CAS  Google Scholar 

  29. FDA Drug Approvals List [online] (cited 14 April 2004). <http://www.fda.gov/cder/foi/label/2003/21385_Ertaczo_lbl.pdf> (2003).

  30. Carrillo-Munoz, A. J. et al. In vitro antifungal activity of sertaconazole against 309 dermatophyte clinical isolates. J. Chemother. 15, 555–557 (2003).

    Article  CAS  Google Scholar 

Download references

Additional information

Authorship This section was authored by Jason LaBonte, John Lebbos, Aarti Raja and Peter Kirkpatrick, and includes material first published in Nature Reviews Drug Discovery. Jason Labonte, John Lebbos and Aarti Raja are at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 02453, USA. Peter Kirkpatrick is at Nature Reviews Drug Discovery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Infectious diseases. Nat Rev Drug Discov 3 (Suppl 7), S26–S32 (2004). https://doi.org/10.1038/nrd1409

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1409

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing